Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer

作者：Qitong Zheng, Chen Wu, Huangshu Ye, Zhenggang Xu, Yang Ji, Jianhua Rao, Ling Lu, Yaqing Zhu, Feng Cheng · 发表于：Annals of Translational Medicine · 年份：2021 · DOI：10.21037/atm-21-4747 · 被引用次数：12 · 研究领域：Cholangiocarcinoma and Gallbladder Cancer Studies、Bladder and Urothelial Cancer Treatments、Gallbladder and Bile Duct Disorders

Background: Gallbladder cancer (GBC) is highly malignant, its early diagnosis is difficult, and the 5-year survival rate is less than 5%. For patients with advanced GBC (GBCa), combined chemotherapy, radiotherapy, targeted therapy, and immunotherapy are needed to improve the overall survival (OS) rate of patients. Methods: Data were collected from 53 patients with GBCa who had volunteered to receive programmed death protein-1 (PD-1)-based treatment at the First Affiliated Hospital of Nanjing Medical University from February 2018 to February 2021. Statistical analysis of the collected data, including Kaplan-Meier method, log-rank test, Cox proportional hazard regression model and other methods. Results: The objective response rates (ORRs) and disease control rates (DCRs) of 53 participants 3 months after receiving immunotherapy were 30.2% and 79.2%, respectively. The ORRs and DCRs of the combined treatment group were higher than those of the camrelizumab group (CG) (P<0.05). The DCRs of the camrelizumab plus apatinib group (CAG) at 3 and 6 months were 90.9% and 45.5% (P=0.003), respectively, while the DCRs at 3 and 6 months of the camrelizumab plus chemotherapy group (CCG) were 85.7% and 71.4% (P=0.450), respectively. After treatment, there were statistically significant differences before and after CA199 for each group (P<0.05). The median progression-free survival (mPFS) of the 53 participants was 7 months, and the median overall survival (mOS) was 12 months. The mPFS and mO...